Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 17/20 | 0.48 |
| ▸ | NR1H3 | Q13133 | 15/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3850564 | 0.82 | NR1H2 (0.41) | NR1H2NR1H3PARP1 | |
| SCHEMBL19012433 | 0.80 | PARP1 (0.44) | PARP1 | |
| SCHEMBL1125010 | 0.80 | CYP2D6 (0.43) | NR1H2NR1H3PARP1MAPK1RECQL | |
| SCHEMBL1124908 | 0.78 | NR1H2 (0.51) | NR1H2NR1H3PARP1 | |
| SCHEMBL4011832 | 0.77 | NR1H2 (0.64) | NR1H2NR1H3 | |
| SCHEMBL27654066 | 0.76 | PARP1 (0.40) | NR1H2NR1H3PARP1USP2TP53 | |
| SCHEMBL1125229 | 0.76 | NR1H2 (0.43) | NR1H2NR1H3PARP1 | |
| SCHEMBL1125479 | 0.76 | NR4A2 (0.43) | NR1H2NR1H3PARP1 | |
| SCHEMBL440370 | 0.75 | PARP1 (0.45) | NR1H2NR1H3PARP1 | |
| SCHEMBL1124802 | 0.75 | PARP1 (0.45) | NR1H2NR1H3PARP1USP2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590948-A1 | NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS | Wyeth LLC (US) | 2013-05-15 | — | — | EP | disclosed |
| CN-103097355-A | Novel quinoline esters useful for treating skin disorders | WYETH LLC | 2013-05-08 | — | — | CN | disclosed |
| WO-2012004748-A1 | NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS | WYETH LLC (US) | 2012-01-12 | — | — | WO | disclosed |
| US-20120010205-A1 | NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS | WYETH LLC (US) | 2012-01-12 | — | — | US | disclosed |
| US-20090069373-A1 | Quinoline Acids | WYETH (US) | 2009-03-12 | — | — | US | disclosed |
| WO-2008049047-A2 | QUINOLINE COMPOUNDS | WYETH (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069373-A1 | Quinoline Acids | NR1H3, NR1H2, NR1H4 | NR1H2 2/4885NR1H3 1/4885PARP1 3366/4885 |
| US-20120010205-A1 | NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885NR1H3 2/4885PARP1 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.